Answers are grounded in this paper and cite their sources.
In vitro study demonstrates that shortening POEGMA side chains boosts tobramycin activity against Pseudomonas aeruginosa while increasing cytotoxicity, indicating a side-chain length trade-off.
Polymer conjugation of cationic antibiotics has emerged as a promising strategy to improve their pharmacological properties and enhance their performance in biofilm-associated infections. Herein, we investigate the effect of poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMA) side-chain length on the physicochemical properties, antimicrobial activity, and biocompatibility of tobramycin (Tob)-POEGMA conjugates. Three alkyne-functional POEGMA copolymers with different oligo(ethylene glycol) side-chain lengths were synthesized by reversible addition–fragmentation chain-transfer (RAFT) polymerization, and subsequently conjugated to azide-functional Tob via Cu(I)-catalyzed azide–alkyne cycloaddition. The aqueous solution behavior of the resulting conjugates was strongly dependent on side-chain length: the polymer bearing the longest side chains remained dissolved, whereas conjugates with shorter side chains self-assembled into positively charged nanoparticles. Antimicrobial evaluation against Pseudomonas aeruginosa PAO1 revealed that decreasing the POEGMA side-chain length enhanced antimicrobial activity, with the shortest-side-chain formulation exhibiting the lowest MIC90 value among the polymer conjugates. However, increased antimicrobial activity was accompanied by increased cytotoxicity toward A549 and Calu-3 epithelial cells. In contrast, longer POEGMA side-chains effectively shielded the cationic Tob residues, resulting in improved biocompatibility but reduced antimicrobial efficacy. These findings demonstrate that POEGMA side-chain length governs the balance between antimicrobial activity and cytocompatibility in Tob-POEGMA conjugates. The results further suggest that long-chain POEGMA represents a promising platform for biofilm-targeted antibiotic delivery when combined with infection-responsive linkers capable of releasing the active antibiotic at the site of infection.
No takes yet. Share an insight, caveat, or question.
Yildirim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: